Fennec Pharmaceuticals (TSE:FRX) Trading Down 0.3% – Time to Sell?

Fennec Pharmaceuticals Inc. (TSE:FRX)’s share price traded down 0.3% during mid-day trading on Thursday . The company traded as low as C$8.55 and last traded at C$8.62. 200 shares were traded during mid-day trading, a decline of 90% from the average session volume of 2,031 shares. The stock had previously closed at C$8.65.

Analysts Set New Price Targets

Separately, Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.

Fennec Pharmaceuticals Trading Down 0.3 %

The stock’s 50-day simple moving average is C$6.83 and its 200-day simple moving average is C$7.72. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 8.02. The firm has a market capitalization of C$235.84 million, a PE ratio of 86.20 and a beta of 0.25.

Insider Activity

In related news, Senior Officer Robert Christopher Andrade bought 15,816 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was bought at an average cost of C$3.43 per share, with a total value of C$54,248.88. Insiders own 16.20% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.